Loading clinical trials...
Loading clinical trials...
A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)
Conditions
Interventions
Simtuzumab
Placebo
Locations
75
United States
Mayo Clinic Hospital
Phoenix, Arizona, United States
University of Arizona Health Sciences Center
Tucson, Arizona, United States
Southern California Liver Center
Chula Vista, California, United States
Southern California Liver Centers
Coronado, California, United States
Scripps Clinic
La Jolla, California, United States
Verterans Adminstration Hospital
Palo Alto, California, United States
Start Date
March 4, 2013
Primary Completion Date
August 8, 2016
Completion Date
August 24, 2016
Last Updated
October 22, 2019
NCT06026865
NCT01161992
NCT06686810
NCT06037577
NCT03766035
NCT05082779
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions